ClinicalTrials.gg
RecruitingNCT07406789LUMInovaUpdated Oct 8, 2026

Phase II, Prospective, Randomized, Proof-of-concept Study to Evaluate the Effects of a Personalized Dietary Intervention in Women With Advanced Gynecologic or Breast Tumors Treated With Antibody-Drug Conjugates (ADCs).

A Phase 2 interventional study of Personalised dietary intervention. and General recommendations in Gynecologic Cancers and Advanced Breast Cancer, sponsored by TNC Nutrición Terapéutica S.L.. Recruiting at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by TNC Nutrición Terapéutica S.L. · Phase 2, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 8, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 905 studies in Breast Neoplasms with a site in Spain — 164 open to participants now, 285 under way, 84 of them phase 3. Breast Neoplasms · Spain.

Planned enrollment
490th of 805
100 · median 151
Started
2026
with 26 others
Phase 2
248 of 905
21 open now
Primary completion
2028-03
later than 201 of 284 live
Registered
880th of 905
by date

Among the 905 studies in Breast Neoplasms with a site in Spain, this one is the 490th largest by planned enrollment of the 805 interventional ones that give a count, is one of 27 that started in 2026, is one of 248 in phase 2, reaches primary completion later than 201 of the 284 other live ones, and was the 880th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

164 of the 905 studies in Breast Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

158 more — sign in →

All 164 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 905 studies in Breast Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

The objective of the study is to evaluate the effect of a personalized dietary intervention (cohort A), compared with a standard nutritional intervention based on general recommendations for following a Mediterranean diet (cohort B), in women with advanced solid tumors of gynecologic or breast origin who are receiving treatment with antibody-drug conjugates (ADCs). This intervention is exclusively nutritional and does not involve the use of any investigational drug.

Read the detailed description

Phase II, proof-of-concept, prospective, interventional, randomized, open-label study designed to evaluate the effect of a personalized dietary intervention on global quality of life in women with advanced gynecologic or breast tumors undergoing treatment with ADCs.

03

Conditions studied

  • Gynecologic Cancers
  • Advanced Breast Cancer

Keywords

  • Breast cancer
  • Diet
  • Cancer
  • Gynecologic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written to participate in the study, obtained prior to performing any specific procedure.
  2. Women aged ≥ 18 years.
  3. Confirmed diagnosis of advanced, incurable (stage IV or unresectable stage III) breast cancer or gynecologic cancer. This includes cancers of the breast, ovary, cervix, uterus, endometrium, fallopian tubes, vagina, or vulva.
  4. Participants must have received a first cycle of ADC treatment in any .
  5. performance status 0-2.
  6. Availability of their main clinical data with the possibility of follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Male patient.
  2. \<18 or > 40 kg/m2.
  3. Patients with a of less than 3 months.
  4. Type 1 diabetes mellitus, metabolic diseases, and severe gastrointestinal disorders that interfere with the digestion or absorption of nutrients, as well as patients with severe renal or hepatic impairment.
  5. Planned participation in treatment within a double-blind clinical trial.
  6. History of previous or concomitant malignant disease of any other type that could affect compliance with the protocol or interpretation of results. Patients with curatively treated basal cell carcinoma of the skin or in situ cervical cancer are eligible for the study.
  7. Presence of concurrent diseases or clinical conditions that, in the investigator's judgment, may significantly interfere with participation in the study, particularly those that limit the ability to adequately use the required digital tools (APP and wearable device). Patients will not be excluded due to common comorbidities if they retain adequate cognitive functioning and digital familiarity to comply with study procedures.
  8. Carriers of therapeutic electronic devices: pacemakers, defibrillators, and cardiac resynchronization devices (due to potential interference caused by the wearable).
  9. Patients who, in the investigator's judgment, do not possess sufficient digital capability to comply with the study procedures.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Cohort A (intervention)

    Personalised dietary intervention, tailored to clinical and metabolic parameters and individual preferences.

    Dietary Supplement: Personalised dietary intervention.

  • Active comparator
    Cohort B (Control)

    General recommendations on the Mediterranean diet, without active dietary intervention.

    Behavioral: General recommendations

Interventions

  • Dietary supplementPersonalised dietary intervention.

    Personalised dietary intervention, tailored to clinical and metabolic parameters and individual preferences.

    Also known as: Personalised diet

  • BehavioralGeneral recommendations

    General recommendations on the Mediterranean diet, without active dietary intervention.

    Also known as: Mediterranean Diet

06

What researchers measure

Primary outcomes

  1. Evaluate the effect of a personalized dietary intervention on health-related quality of life (HRQoL), compared with general recommendations for a Mediterranean diet, in women with advanced gynecologic or breast tumors treated with ADCs.

    Quality of life will be measured using the validated EORTC QLQ-C30 questionnaire, considering as the primary variable the percentage of patients experiencing clinically relevant improvement, defined as an increase of ≥10 points in the overall score from baseline.

    Time frame: 24 months

Secondary outcomes

  1. Evaluate changes in mental health and psychological well-being.

    Assess changes in mental health and psychological well-being using the GHQ-28 questionnaire. The assessment variable will be the change from the baseline score in the total result and in each of the subscales (somatic symptoms, anxiety/insomnia, social dysfunction, and severe depression). Patients will be classified into those with emotional distress and those without, and the evolution of the distribution will be observed throughout the follow-up.

    Time frame: 24 months

  2. Evaluate perceived toxicity and treatment-related symptoms.

    Evaluate perceived toxicity and treatment-related symptoms through the PRO-CTCAE v5.0 questionnaire, focusing on adverse events of special interest including fatigue, nausea and vomiting, diarrhea, peripheral neuropathy, conjunctivitis, blurred vision and dry eyes, neutropenia, rash, alopecia, anemia, and hand-foot syndrome.

    Time frame: 24 months

Other outcomes

  1. Assess progression-free survival in real life (rwPFS)

    Defined as the time from randomisation to clinical progression (based on symptomatic or radiological criteria or change in treatment due to progression) or death, whichever occurs first.

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
  • Hospital Universitario 12 Octubre
    Madrid, Madrid, Spain
    Recruiting
    • Luis Manso, MD · Contact
    • Luis Manso, MD · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 24 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: start Feb 2026 → Mar 2026, primary completion Feb 2028 → Mar 2028 and completion Feb 2028 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2026
First posted
Feb 12, 2026
StartActual
Mar 10, 2026was Feb 2026
Primary completionEst.
Mar 10, 2028was Feb 2028
CompletionEst.
Mar 10, 2028was Feb 2028
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 8, 2026
Sites
Hospital Universitario 12 Octubre is now Recruiting
Oct 8, 2026
Start date
Feb 11, 2026→Mar 10, 2026 (actual)
Oct 8, 2026
Primary completion
Feb 11, 2028→Mar 10, 2028
Oct 8, 2026
Study completion
Feb 11, 2028→Mar 10, 2028
Oct 8, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Hospital Universitario 12 Octubre · Madrid, SpainContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Not yet recruiting→Recruiting
    Hospital Universitario 12 Octubre is now Recruiting
    Start date Feb 11, 2026→Mar 10, 2026 (now actual)
    Primary completion Feb 11, 2028→Mar 10, 2028
    Study completion Feb 11, 2028→Mar 10, 2028
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Hospital Universitario 12 Octubre · Madrid, SpainContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07406789
Lead sponsor
TNC Nutrición Terapéutica S.L.
Collaborators
Apices Soluciones S.L.
Responsible party
Sponsor
First posted
Feb 12, 2026
Start date
Mar 10, 2026
Primary completion
Mar 10, 2028 (estimated)
Completion
Mar 10, 2028 (estimated)
Last update
Oct 8, 2026

Study contacts

TNC Nutrición Terapéutica S.L
Contact
info@tncterapia.com
+34 672 567 899

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion